Brain eicosapentaenoic acid metabolism as a lead for novel therapeutics in major depression
dc.rights.license | open | en_US |
dc.contributor.author | BAZINET, Richard P. | |
dc.contributor.author | METHEREL, Adam H. | |
dc.contributor.author | CHEN, Chuck T. | |
dc.contributor.author | SHAIKH, Saame Raza | |
hal.structure.identifier | Nutrition et Neurobiologie intégrée [NutriNeuro] | |
dc.contributor.author | NADJAR, Agnes | |
hal.structure.identifier | Nutrition et Neurobiologie intégrée [NutriNeuro] | |
dc.contributor.author | JOFFRE, Corinne | |
hal.structure.identifier | Nutrition et Neurobiologie intégrée [NutriNeuro] | |
dc.contributor.author | LAYE, Sophie
ORCID: 0000-0002-3843-1012 IDREF: 11366883X | |
dc.date.accessioned | 2021-09-06T08:42:09Z | |
dc.date.available | 2021-09-06T08:42:09Z | |
dc.date.issued | 2019-07-03 | |
dc.identifier.issn | 1090-2139 | en_US |
dc.identifier.uri | https://oskar-bordeaux.fr/handle/20.500.12278/112091 | |
dc.description.abstractEn | The results of several meta-analyses suggest that eicosapentaenoic acid (EPA) supplementation is therapeutic in managing the symptoms of major depression. It was previously assumed that because EPA is extremely low in the brain it did not cross the blood-brain barrier and any therapeutic effects it exerted would be via the periphery. However, more recent studies have established that EPA does enter the brain, but is rapidly metabolised following entry. While EPA does not accumulate within the brain, it is present in microglia and homeostatic mechanisms may regulate its esterification to phospholipids that serve important roles in cell signaling. Furthermore, a variety of signaling molecules from EPA have been described in the periphery and they have the potential to exert effects within the brain. If EPA is confirmed to be therapeutic in major depression as a result of adequately powered randomized clinical trials, future research on brain EPA metabolism could lead to the discovery of novel targets for treating or preventing major depression. | |
dc.language.iso | EN | en_US |
dc.title.en | Brain eicosapentaenoic acid metabolism as a lead for novel therapeutics in major depression | |
dc.type | Article de revue | en_US |
dc.identifier.doi | 10.1016/j.bbi.2019.07.001 | en_US |
dc.subject.hal | Sciences du Vivant [q-bio]/Neurosciences [q-bio.NC] | en_US |
dc.identifier.pubmed | 31278982 | en_US |
bordeaux.journal | Brain, Behavior, and Immunity | en_US |
bordeaux.page | 21-28 | en_US |
bordeaux.volume | 85 | en_US |
bordeaux.hal.laboratories | NutriNeurO (Laboratoire de Nutrition et Neurobiologie Intégrée) - UMR 1286 | en_US |
bordeaux.institution | Université de Bordeaux | en_US |
bordeaux.institution | INRAE | en_US |
bordeaux.team | Psychoneuroimmunologie et Nutrition: Approches expérimentales et cliniques | en_US |
bordeaux.peerReviewed | oui | en_US |
bordeaux.inpress | non | en_US |
hal.export | false | |
dc.rights.cc | Pas de Licence CC | en_US |
bordeaux.COinS | ctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=Brain,%20Behavior,%20and%20Immunity&rft.date=2019-07-03&rft.volume=85&rft.spage=21-28&rft.epage=21-28&rft.eissn=1090-2139&rft.issn=1090-2139&rft.au=BAZINET,%20Richard%20P.&METHEREL,%20Adam%20H.&CHEN,%20Chuck%20T.&SHAIKH,%20Saame%20Raza&NADJAR,%20Agnes&rft.genre=article |
Fichier(s) constituant ce document
Fichiers | Taille | Format | Vue |
---|---|---|---|
Il n'y a pas de fichiers associés à ce document. |